Leukocytoclastic Vasulitis Induced by Methoxy Polyethylene Glycol-Epoetin Beta.
- Author:
Sang Yoon LEE
1
;
Jae Wan GO
;
Shin Han KIM
;
Hyun Ok SON
;
Han Kyoung CHO
Author Information
1. Department of Dermatology, Kwandong University College of Medicine, Goyang, Korea. dermy@kd.ac.kr
- Publication Type:Case Report
- Keywords:
Leukocytoclastic vasculitis;
Methoxy polyethylene glycol-epoetin beta;
Mircera(R)
- MeSH:
Anemia;
Diarrhea;
Erythema;
Erythropoietin;
Humans;
Hypertension;
Nasopharyngitis;
Polyethylene;
Polyethylene Glycols;
Receptors, Erythropoietin;
Renal Insufficiency, Chronic;
Tinea Pedis;
Vasculitis;
Vasculitis, Leukocytoclastic, Cutaneous
- From:Korean Journal of Dermatology
2013;51(1):49-52
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Methoxy polyethylene glycol-epoetin beta (Mircera(R), Roche), a third-generation erythropoiesis-stimulating agent (ESA) is known as a continuous erythropoietin receptor activator (CERA). In patients with anemia associated with chronic kidney disease (CKD), it is administered intravenously or subcutaneously. Treatment-related adverse events induced by methoxy polyethylene glycol-epoetin beta occurred in 6%. Hypertension, diarrhea and nasopharyngitis were the most commonly reported adverse events. Cutaneous adverse reactions are rarely experienced with methoxy polyethylene glycol-epoetin beta including maculopapular eruption, facial erythema, and tinea pedis. To the best of our knowledge, no cases of leukocytoclastic vasculitis associated with methoxy polyethylene glycol-epoetin beta have ever been published in medical literature. Herein, we report on a case of leukocytoclastic vasulitis induced by methoxy polyethylene glycol-epoetin beta in a patient with anemia associated with chronic kidney disease.
